BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 32232676)

  • 1. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
    Cornes P; Gascon P; Vulto AG; Aapro M
    BioDrugs; 2020 Jun; 34(3):255-263. PubMed ID: 32232676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
    Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
    Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 7. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
    Aapro M; Boccia R; Leonard R; Camps C; Campone M; Choquet S; Danova M; Glaspy J; Hus I; Link H; Sliwa T; Tesch H; Valero V
    Support Care Cancer; 2017 Nov; 25(11):3295-3304. PubMed ID: 28842778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
    Liu Z; Doan QV; Malin J; Leonard R
    Appl Health Econ Health Policy; 2009; 7(3):193-205. PubMed ID: 19799473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RGB-02 (biosimilar pegfilgrastim) in the treatment of chemotherapy-induced neutropenia.
    Sántha D; Illés A; Aradi I; Horvát-Karajz K; Kahán Z
    Future Oncol; 2019 Jun; 15(18):2083-2092. PubMed ID: 31210542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM; Allcott K; Pettengell R; von Minckwitz G; Schwenkglenks M; Szabo Z
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
    Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
    Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
    Aapro MS; Chaplin S; Cornes P; Howe S; Link H; Koptelova N; Mehl A; Di Palma M; Schroader BK; Terkola R
    Support Care Cancer; 2023 Sep; 31(10):581. PubMed ID: 37728795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
    McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
    J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
    [No Abstract]   [Full Text] [Related]  

  • 15. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
    De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
    Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
    Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
    Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
    Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
    BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework.
    Wang W; Li E; Campbell K; McBride A; D'Amato S
    JCO Oncol Pract; 2021 Aug; 17(8):e1139-e1149. PubMed ID: 33961490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
    Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
    BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.